Northland Securities Reiterates “Buy” Rating for Esperion Therapeutics, Inc. (ESPR)

Northland Securities reissued their buy rating on shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) in a report issued on Friday morning. Northland Securities currently has a $72.00 price objective on the biopharmaceutical company’s stock.

ESPR has been the subject of a number of other research reports. BidaskClub lowered Esperion Therapeutics from a strong-buy rating to a buy rating in a research report on Friday, August 4th. Cowen and Company initiated coverage on Esperion Therapeutics in a research report on Thursday, September 7th. They set an outperform rating and a $64.00 price objective for the company. Stifel Nicolaus restated a buy rating and set a $70.00 price objective on shares of Esperion Therapeutics in a research report on Wednesday, October 4th. Deutsche Bank AG set a $64.00 price objective on Esperion Therapeutics and gave the company a buy rating in a research report on Wednesday, August 9th. Finally, Needham & Company LLC raised their price objective on Esperion Therapeutics from $58.00 to $72.00 and gave the company a positive rating in a research report on Tuesday, August 8th. Six research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. The stock has an average rating of Buy and an average price target of $58.92.

Esperion Therapeutics (ESPR) opened at $47.22 on Friday. Esperion Therapeutics has a 12-month low of $10.30 and a 12-month high of $57.40.

Esperion Therapeutics (NASDAQ:ESPR) last issued its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($1.86) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.79) by ($0.07). During the same quarter in the previous year, the firm posted ($0.77) earnings per share. equities analysts forecast that Esperion Therapeutics will post -7.21 EPS for the current year.

TRADEMARK VIOLATION WARNING: “Northland Securities Reiterates “Buy” Rating for Esperion Therapeutics, Inc. (ESPR)” was reported by BBNS and is owned by of BBNS. If you are viewing this article on another domain, it was illegally copied and republished in violation of international copyright legislation. The correct version of this article can be accessed at https://baseballnewssource.com/markets/northland-securities-reiterates-buy-rating-for-esperion-therapeutics-inc-espr/1774066.html.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. US Bancorp DE grew its position in Esperion Therapeutics by 1.1% in the second quarter. US Bancorp DE now owns 9,856 shares of the biopharmaceutical company’s stock worth $457,000 after acquiring an additional 104 shares in the last quarter. American International Group Inc. grew its position in Esperion Therapeutics by 7.1% in the first quarter. American International Group Inc. now owns 8,814 shares of the biopharmaceutical company’s stock worth $311,000 after acquiring an additional 584 shares in the last quarter. Voya Investment Management LLC grew its position in Esperion Therapeutics by 12.7% in the second quarter. Voya Investment Management LLC now owns 7,148 shares of the biopharmaceutical company’s stock worth $331,000 after acquiring an additional 806 shares in the last quarter. TIAA CREF Investment Management LLC grew its position in Esperion Therapeutics by 3.0% in the second quarter. TIAA CREF Investment Management LLC now owns 39,074 shares of the biopharmaceutical company’s stock worth $1,808,000 after acquiring an additional 1,148 shares in the last quarter. Finally, Alliancebernstein L.P. boosted its position in shares of Esperion Therapeutics by 5.3% during the second quarter. Alliancebernstein L.P. now owns 30,070 shares of the biopharmaceutical company’s stock valued at $1,392,000 after buying an additional 1,500 shares during the period. Institutional investors own 89.12% of the company’s stock.

About Esperion Therapeutics

Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.

Analyst Recommendations for Esperion Therapeutics (NASDAQ:ESPR)

Receive News & Ratings for Esperion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Alex Cobb Could Be Good Fit for Cubs
Alex Cobb Could Be Good Fit for Cubs
Joey Votto Is One of Baseball’s Best Hitters
Joey Votto Is One of Baseball’s Best Hitters
Hunter Pence May Become Part-Time Player
Hunter Pence May Become Part-Time Player
Perfect 300 Bowled by Red Sox Right Fielder Mookie Betts
Perfect 300 Bowled by Red Sox Right Fielder Mookie Betts
Brandon Morrow Becomes Hot Commodity
Brandon Morrow Becomes Hot Commodity
Red Sox Want Sluggers, Giancarlo Stanton May Become Available
Red Sox Want Sluggers, Giancarlo Stanton May Become Available


Leave a Reply

 
© 2006-2017 BBNS.